![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Kluetz Paul G Figg William D Dahut William L
Publisher: Informa Healthcare
ISSN: 1465-6566
Source: Expert Opinion on Pharmacotherapy, Vol.11, Iss.2, 2010-02, pp. : 233-247
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Angiogenesis inhibitors in the treatment of cancer
Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 10, 2005-08 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
CYP17 Inhibitors for Prostate Cancer Treatment - An Update
Current Medicinal Chemistry, Vol. 15, Iss. 9, 2008-04 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
VEGF Inhibitors and Prostate Cancer Therapy
Current Molecular Pharmacology, Vol. 2, Iss. 2, 2009-06 ,pp. :